Navigation Links
Patient with rare disorder responds to cancer drug
Date:2/13/2008

A rare disorder caused by an excess of two types of immune cellsthe mast cell found in various tissues and its blood-based twin, the basophilhas successfully been treated with a cancer drug, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study, now available online at the Web site of the journal Haematologica, was a collaborative effort led by Dean Metcalfe, M.D., chief of the NIAID Laboratory of Allergic Diseases and Jan Cools, Ph.D., a staff scientist, at the Katholieke Universiteit Leuven within the Vlaams Institute for Biotechnology and the Department of Molecular and Developmental Genetics, in Leuven, Belgium.

A few years ago, the 61-year-old patient was referred to the NIH Clinical Center because he was quite ill with symptoms of systemic mastocytosis, a disease caused by excessive numbers of mast cells, and chronic basophilic leukemia, a rare type of bone marrow cancer characterized by an overabundance of basophils.

Systemic mastocytosis often results from a mutation in the gene that codes for the KIT receptor found on the surface of mast cells, a discovery first made by Dr. Metcalfe and his team in 1995. In this patient, however, the KIT receptor mutation was ruled out. In further studies, NIAID researchers and their collaborators found a chromosomal abnormality that led to the discovery of a fusion protein in the cell, created by two genes joining together. They also found that the fusion protein was the basis of the disorder and figured that the patient should respond to imatinib, a drug already approved to treat different types of cancers and systemic mastocytosis. After the patient was treated with the cancer drug imatinib, his clinical symptoms improved quickly and dramatically, and he remains in clinical remission three years after treatment was started.

This is a rare report of the simultaneous occurrence of these two conditions in one patient, and the first describing a response to therapy. Diagnosing a patient who has such an atypical disorder can be difficult, says Dr. Metcalfe. Recently, another patient with similar clinical findings was referred to their clinic. Based on their experience with the first patient, the researchers started treatment with imatinib and, according to Dr. Metcalfe, this patient also is responding well.

Identifying this newly recognized chromosomal abnormality and the fusion protein in patients who present with clinical findings of systemic mastocytosis and chronic basophilic leukemia may enable doctors to successfully treat these individuals with imatinib, according to Dr. Metcalfe.


'/>"/>

Contact: Sitara Maruf
marufs@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems
2. Tango Classes Put Parkinsons Patients a Step Ahead
3. Arizona Nurses Rally at Capitol for Patient Safety - Thursday
4. HPV-positive head and neck cancer patients fare better than HPV-negative patients
5. DCIS patients overestimate breast cancer risks
6. Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks
7. New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety
8. Precious Time - Scientists discover how long heart failure patients can expect to live
9. Michigan Kidney Patient Goes Above and Beyond to Help His Community - Awarded National DPC Hero Award
10. Patients with larger social networks may fare better after an operation
11. A new agent for the treatment of patients with myelodysplastic syndrome; and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has ... bony lump located on the forehead usually attributed to a facial fracture. Their appearance ... Dr. Shah has discovered an approach that is minimally invasive. He is an expert ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Dudnyk has ... identity emphasizes the agency’s conviction that the full potential of specialty and orphan brands ... equally appreciated and aligned. , “The Unifying Effect is at the heart of ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic ... 3D printing facility among higher education institutions in Hong Kong to support teaching, learning ... of the range and quantity of facilities in Hong Kong. , With an ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway ... new partnership with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Providing for loved ... the estate planning process, or where to even begin. “Now more than ever there ... are to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, founder ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: